	SASE PERIOD EXP	LIVILIVOL									Page 1 of 8
I. General Information									OMB	Approved # 0938-0944 (E	PD-2020.1 Expires: 2/28/2021)
Contract Number:		4. Contract Yr:	2020		7. Plan Name:			10. VBID:	N	13. PD Region:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2. Plan ID:		5. Org. Name:		_	8. Plan Type:			11. MTM:	N	14. PD Benefit Type:	
3. Segment ID:		6. SNP:			9. Enrollee Type:			12. ESRD-SNP:	N	• • •	N/A
Ü			· ·		,,					, , , , , , , , , , , , , , , , , , ,	
II. Base Period Background	Information										
Time Period Definition				2a. Total Member M		0	5. Mapping	Contr-Plan-Seg ID	Member Months	Contr-Plan-Seg ID	Member Months
Incurred from: Incurred to:				2b. LIS Member Mor3. Risk Score	ntns						
Paid through:				4. Completion Factor	r						
raid till odgil.				4. Completion racto							
III. Bort D Claims Eversions											
III. Part D Claims Experience	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(1)	(m)	(n)
	Total Count		(1)	(9)	(11)	(1)	Cumulative	(R)	(1)	(111)	(11)
	Total oddine	III IIICOI VAI					Gamaianve	Adiustmen	ts to Reflect Pt. D) Coverage	
Allowed			Total	Total	Average	Average	Average	Supplemental	Reimb for	Reimb	Net Plan
Claim	# of	Member	Number of	Allowed	Allowed Amount	Paid Amount	Cost Sharing	C.S. Reduc.	LIS	for Fed Reins.	Responsibility
Interval	Members	Months	Scripts	Dollars	per Member	per Member	per Member	per Member	per Member	per Member	per Member
1. \$0					\$0.00						\$0.00
1. \$0 2. \$1-\$404 3. \$405-\$3,749					\$0.00						\$0.00
3. \$405-\$3,749											
					\$0.00						\$0.00
4. \$3,750-Catastrophic *					\$0.00						\$0.00
4. \$3,750-Catastrophic *5. Above Catastrophic *					\$0.00 \$0.00					••••	\$0.00 \$0.00
4. \$3,750-Catastrophic *5. Above Catastrophic *6. Subtotal	0		0 0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
4. \$3,750-Catastrophic *5. Above Catastrophic *	0		0 0	\$0.00	\$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00
 4. \$3,750-Catastrophic * 5. Above Catastrophic * 6. Subtotal 7. % OON 	0		0 0		\$0.00 \$0.00 \$0.00		\$0.00				\$0.00 \$0.00 \$0.00
 4. \$3,750-Catastrophic * 5. Above Catastrophic * 6. Subtotal 7. % OON 8. PMPM Values 	0		0 0	\$0.00	\$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00 \$0.00	\$0.00 \$0.00	\$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00
 4. \$3,750-Catastrophic * 5. Above Catastrophic * 6. Subtotal 7. % OON 8. PMPM Values 9. Minus Rebates 	0		0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00	\$0.00				\$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 4. \$3,750-Catastrophic * 5. Above Catastrophic * 6. Subtotal 7. % OON 8. PMPM Values 9. Minus Rebates 10. Plus Part D as Secondary 	t PMPM		0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun 			0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00	\$0.00				\$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplementa 	l Drugs		0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun 	l Drugs Drugs		0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplemental Rebates on Supplemental I Net PMPM on Supplemental 	l Drugs Drugs Ital Drugs	Plan BPT for CY202	0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplemental Rebates on Supplemental I 	l Drugs Drugs Ital Drugs	Plan BPT for CY202	0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplemental Rebates on Supplemental I Net PMPM on Supplemental 	I Drugs Drugs Ital Drugs Ing the Prescription Drug	Plan BPT for CY202	0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00		\$0.00 \$0.00	\$0.00	\$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplemental Rebates on Supplemental Net PMPM on Supplement * See Instructions for Completion 	I Drugs Drugs Ital Drugs Ing the Prescription Drug	Plan BPT for CY202	0 0		\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00	Statement Summ	\$0.00 \$0.00	\$0.00	\$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00
 \$3,750-Catastrophic * Above Catastrophic * Subtotal % OON PMPM Values Minus Rebates Plus Part D as Secondary Net Average Paid Amoun Non-covered Supplemental Rebates on Supplemental Net PMPM on Supplement * See Instructions for Completion 	I Drugs Drugs Ital Drugs Ing the Prescription Drug	Plan BPT for CY202	0 0	\$0.00	\$0.00 \$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00	Statement Summ	\$0.00 \$0.00	\$0.00	\$0.00 \$0.00	\$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00

Direct Administration Indirect Administration Net Cost of Private Reinsurance Insurer Fees 6. Total Non-Benefit Expenses

		(e)	(f)	(g)
		Basic	Supplemental	Total
1.	CMS Part D Payment			\$0.00
2.	LI Premium Subsidy			\$0.00
3.	Member Premium			\$0.00
5.	Total Premium	\$0.00	\$0.00	\$0.00

VI. PMPM Income Statement Summary	(m)
1. Premium Revenue	\$0.00
2. LIS Reimb.	\$0.00
3. Fed Reins.	\$0.00
4. Allocated Buy-Down*	
5. Total Revenue	\$0.00
6. Pharmacy Claims	\$0.00
7. Non-Benefit Expenses	\$0.00
8. Total Expenses	\$0.00
•	·
9. Gain/(Loss) Including Buy-Down	\$0.00

* MA rebate dollars to buy-down Part D premium (not true revenue)

Total Non-LI Brand Discount Amount	

PRA Disclosure Statement According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0938-0944. The time required to complete this information collection is estimated to average 12 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.

V. PMPM Premium Revenue

Contract Num	4. Contract Yr:	2020	7. Plan Name:	10. VBID:	N	13. PD Region:	
2. Plan ID:	5. Org. Name:		8. Plan Type:	11. MTM:	N	14. PD Benefit Type:	
3. Segment ID:	6. SNP:		9. Enrollee Type	12. ESRD-SNP:	N	15. SNP Type:	N/A

II. Utilization for Covered Part D Drugs

	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)	(o)
		Base Period			Compone	ents of Utilization	Change				
	# of								Total	Projected	
	Scripts/	Allowed	PMPM	Trend in	Formulary	Risk	Induced	Other	Utilization	Scripts/	
Type of Script	1000	per Script	Allowed	Scripts/1000	Change	Change	Utilization*	Change	Change	1000	Covariance
Retail Generic			\$0.00						0.000	0	0.000
Retail Preferred Brand			\$0.00						0.000	0	0.000
Retail Non-Preferred Brand			\$0.00						0.000	0	0.000
4. Retail Specialty			\$0.00						0.000	0	0.000
5. Mail Order Generic			\$0.00						0.000	0	0.000
6. Mail Order Preferred Brand			\$0.00						0.000	0	0.000
7. Mail Order Non-Preferred Brand			\$0.00						0.000	0	0.000
8. Mail Order Specialty			\$0.00						0.000	0	0.000
9. Total Retail	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
10. Total Mail Order	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
11. Total Generic	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
12. Total Brand (Preferred and Non-Preferred	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
13. Total Specialty	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000
14. Total	(\$0.00	\$0.00	0.000	0.000	0.000	0.000	0.000	0.000	0	0.000

^{*}Adjustment to remove impact of induced utilization due to supplemental coverage

III. Cost for Covered Part D Drugs

III. Cost for Covered Part D Drugs								IV. Projected	Allowed PMPM	l		
	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)	(o)	(p)
		Compone	ents of Unit Cost C	hange		Projected	Projected	Manual	Manual	Manual		Blended
	Inflation	Discount	Formulary	Other	Tot. Unit	Unit	Allowed	Util/	Unit	Rate		Allowed
	Trend	Change	Change	Change	Cost Chg	Cost	PMPM	1000	Cost	PMPM	Credibility	PMPM
Retail Generic					0.000	\$0.00	\$0.00			\$0.00		\$0.00
Retail Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
Retail Non-Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
4. Retail Specialty					0.000	\$0.00	\$0.00			\$0.00		\$0.00
5. Mail Order Generic					0.000	\$0.00	\$0.00			\$0.00		\$0.00
6. Mail Order Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
7. Mail Order Non-Preferred Brand					0.000	\$0.00	\$0.00			\$0.00		\$0.00
8. Mail Order Specialty					0.000	\$0.00	\$0.00			\$0.00		\$0.00
9. Total Retail	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
10. Total Mail Order	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
11. Total Generic	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
12. Total Brand (Preferred and Non-Preferred	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
13. Total Specialty	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
14. Total	0.000	0.000	0.000	0.000	0.000	\$0.00	\$0.00	0	\$0.00	\$0.00	0%	\$0.00
									CMS Guidelin	e Credibility	0%	

٧.	PMPM	Non-Benefit	Expenses
----	-------------	-------------	-----------------

-	` '
	Projected Expenses
 Sales and Marketing 	
2. Direct Administration	
3. Indirect Administration	
4. Net Cost of Private Reinsurance	
5. Insurer Fees	
6. Total Non-Benefit Expenses	\$0.00

VI. Percentage of Revenue

VII. I Crocintage of Nevertae	U/
	at 0.000
1. Claims (Allowable Cost Target):	\$0.0
2. Non-Benefit Expenses	\$0.0
3. Gain/(Loss):	\$0.0
4. Total Basic Bid	\$0.0
5. Percentage of Revenue	
a. Claims (Allowable Cost Target):	0.09
b. Non-Benefit Expenses	0.09
c. Gain/(Loss):	0.09

. Contract Number:	4. Contract Yr:	2020	7. Plan Name:	10. VBID:	N	13. PD Region:	
2. Plan ID:	5. Org. Name:		8. Plan Type:	11. MTM:	N	14. PD Benefit Type:	
3. Segment ID:	6. SNP:		9. Enrollee Type:	12. ESRD-SNP:	N	15. SNP Type:	N/A

II. Projection Data

1. Projected Member Months:	0	2. Projected Avg Risk Score:	3. Projected LIS Member Months:	
			4. Projected non-LIS Member Months: 0	

III. Part D Covered Drug Claims

iii. Tare 5 covered 5 rag claims	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(I)	(m)	(n)	(o)
Allowed					Avg Amt				Other			Federal
Claim	# of	Member	# of	Projected	Allowed		Gap	PMPM	Cost Sharing	Federal	Plan Liability	LICS
Interval	Members	Months	Scripts	Allowed	PMPM	Cost Sharing	PMPM	Deductible	PMPM	Reins. PMPM	PMPM	PMPM
1. \$0					\$0.00						\$0.00	
2. \$1-\$414					\$0.00	\$0.00					\$0.00	
3. \$415-\$3,819					\$0.00	\$0.00					\$0.00	
4. \$3,820-Catastrophic					\$0.00	\$0.00					\$0.00	
5. Above Catastrophic					\$0.00	\$0.00					\$0.00	
6. Subtotal	0		0 0	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
7. Minus Rebates					\$0.00					\$0.00	\$0.00	
8. Plus Part D as Secondary					\$0.00				1		\$0.00	
9. Projected % OON Included above:	Allowed:											
10. 11. Total	Plan Liability:			\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

IV. Non-Benefit Expenses and Gain/(Loss)

1.	Basic Non-Benefit Expenses	\$0.00
2.	Supplemental Non-Benefit Expenses	\$0.00
3.	Total Non-Benefit Expenses	\$0.00
4.	Basic Gain/(Loss)	\$0.00
5.	Supplemental Gain/(Loss)	\$0.00
6.	Total Gain/(Loss)	
_		

7.	Overall Gain/(Loss) Margin Level
8.	Corporate Margin Requirement % of Rev.
9	Corporate Margin Basis

-		- 3		
				-
10	la thia hid n	ort of	a valid product pairing?	

V. Defined Standard Coverage Bid Development

	(i)	(j)
	At 0.000	At 1.00
1. Claims (Allowable Cost Target):	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance:	\$0.00	\$0.00

10. Is this bid part of a valid product pairing?	
11 Bids in Product Pairing	

Page 4 of 8

Contract Number:	4. Contract Yr:	2020	7. Plan Name:	10. VBID: N	13. PD Region:	
2. Plan ID:	5. Org. Name:		8. Plan Type:	11. MTM: N	14. PD Benefit Type	: :
3. Segment ID:	6. SNP:		9. Enrollee Type:	12. ESRD-\$N	15. SNP Type:	N/A

II. Projection Data

I. General Information

1. Projected Member months	0	2. Projected Avg Risk Score	0.000	

III. Development of Bid for Standard Coverage

	At 0.000	At 1.00
1. Claims (Allowable Cost Target)	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance	\$0.00	\$0.00
6. LIS	\$0.00	

V. Std. Cov. Bid Development with Actuarially Equivalent C. S.

	At 0.000	At 1.00
1. Claims (Allowable Cost Target)	\$0.00	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss):	\$0.00	\$0.00
4. Total Basic Bid	\$0.00	\$0.00
5. Federal Reinsurance	\$0.00	\$0.00
6. LIS		

IV: Development of Bid Components and Tests for Actuarial Equivalence

(e) (g) (i)

	(6)	(9)	(1)	(1)
1. Total Members				0
2. Member Months				0
2. WEITIGET WOTERS	Amounts below	Amounts in	Amounts above	All
	Initial Coverage Limit	Gap	Catastrophic Threshold	Amounts
	<\$3,820		ошистории и постои	7
Allowed PMPM	. ,			
3. Standard	\$0.00	\$0.00	\$0.00	\$0.00
4. Standard with Act. Equiv. Cost Sharing	\$0.00	\$0.00	\$0.00	\$0.00
5. Value of Deductible	\$0.00	\$0.00	\$0.00	\$0.00
Allowed Subject to Coins.				
6. Standard	\$0.00	\$0.00	\$0.00	\$0.00
7. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Coins. %				
8. Standard	25.0% A	0.0%	0.0% C	0.0%
9. Standard with Act. Equiv. Sharing	В	0.0%	0.0% D	0.0%
Coins PMPM				
10. Standard	\$0.00	\$0.00	\$0.00	\$0.00
11. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Net Cost of Benefit				
12. Standard	\$0.00	\$0.00	\$0.00	\$0.00
13. Standard with Act. Equiv. Sharing	\$0.00	\$0.00	\$0.00	\$0.00
Rebates			For Reinsurance	Inc Reins.
14. Standard			\$0.00	\$0.00
15. Standard with Act. Equiv. Sharing			\$0.00	
Test for Actuarial Equivalence				
Effective coinsurance with alternative cost	sharing = to effective coinsurance for star	ndard cost sharing		
16. A=B	No			
17. C=D	No			
18. Coverage in the Gap	No			

Contract Numbe	4. Contract Yr:	2020	7. Plan Name:	10. VBID:	N	13. PD Region:	
2. Plan ID:	5. Org. Name:		8. Plan Type:	11. MTM:	N	14. PD Benefit Type:	
3. Segment ID:	6. SNP:		9. Enrollee Type:	12. ESRD-SNP:	N	15. SNP Type: N/A	

II. Projection Data

 -				
 Projected Member months 	0	2. Projected Avg Risk Score	0.000	

III. Development of Bid for Standard Coverage

	At 0.000		At 1.00
1. Claims	\$0.00	С	\$0.00
2. Non-Benefit Expenses	\$0.00		\$0.00
3. Gain/(Loss)	\$0.00		\$0.00
4. Total Basic Bid	\$0.00		\$0.00
5. Federal Reinsurance	\$0.00		\$0.00
6. Total Coverage	\$0.00	Α	\$0.00
7. LIS	\$0.00		

V. Development of Actuarial Equivalence Test

	At 0.000	At 1.00
1. Part D Covered Drugs	\$0.00 D	\$0.00
2. Non-Benefit Expenses	\$0.00	\$0.00
3. Gain/(Loss)	\$0.00	\$0.00
4. Federal Reinsurance	\$0.00	\$0.00
5. Total Part D Covered	\$0.00 B	\$0.00
6. Non-Part D Covered Drugs	\$0.00	
7. Total Plan Coverage	\$0.00	
8. Total Basic Bid	\$0.00	\$0.00
9. LIS		

IV. Development of Bid Components

IV. Development of Bid Components		(~)	/ :\	(14)	(100)	(0)	(~)
Г	(d) (f)	(g)	(i)	(k)	(m)	(o)	(q)
	Members with	Members	Amounts <=ICL	overed Drugs	Amts above	All	<u> </u>
	<\$3,820	>=\$3,820	for all members		Catastrophic	Members	
Population not Meeting Deductible		>=\$3,620	0		Oatastropriic 0	()	
Population Meeting Deductible Population Meeting Deductible	0	0	0		0	0	
Member Months	0	0	0		0	0	
3. Weinser Workins	Type o	f Deductible		Type of Gap Coverage			Non-
	Alt Coverage Deduct		E	Alternative Coverage ICL		Total	Part D
Allowed PMPM	_	low Initial Cove		Amts in Gap	Amts above Catastrophic	PMPM	Covd
4. Standard	\$0.00		\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
5. Alternative	\$0.00	•	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Deductible	·	·	·	·	,	·	·
6. Value of \$415 Deductible			\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
7. Value of Proposed Deductible			\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Allowed Subject to Coins.			Ş0.00	Ç0.00	\$0.00	Ş0.00	\$0.00
8. Standard	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
9. Alternative	\$0.00	•	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Coins. %	φο.σσ	φο.σσ	φ0.00	φο.σσ	φ0.00	φο.σσ	\$0.00
10. Standard	25.0%	25.0%	0.0%	100.0% J	0.0% H		0.0%
11. Alternative			0.0%	0.0% K	0.0% I		0.0%
Coins PMPM							
12. Standard	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
13. Alternative	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
Federal Reinsurance							
14. Standard					\$0.00	\$0.00	\$0.00
15. Alternative					\$0.00	\$0.00	\$0.00
Minus Rebates					For Reinsurance	Inc Reins.	
16. Standard					\$0.00	\$0.00	\$0.00
17. Alternative					\$0.00		
Plus Part D as Secondary							
18. Standard					\$0.00	\$0.00	\$0.00
19. Alternative							
Net Cost of Benefit							
20. Standard	\$0.00			\$0.00	\$0.00	\$0.00	\$0.00
21. Alternative	\$0.00	\$0.00 G	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

VI. Tests for Alternative Coverage:

1. Total Coverage >= Std Coverage (B>=A)	Yes
2. Unsubsidized value>= Unsub Value for Std Covg(1=yes and D>=C)	Yes
3. Average Cost at Initial Covg Limit >= Std (G >=F)	Yes
4. Deductible <=\$415 (E <=415)	Yes
5. Average Catastrophic cost sharing <= Std (I <= H)	Yes
6. Coverage in the Gap (K <= J)	Yes

VIII. Development of Induced Utilization Adjustment

	At 0.000	At 1.00
1. Claims for Standard	\$0.00	\$0.00
2. Impact of Alternative Utilization on Standard		\$0.00
3. Allowable Cost Target for Alternative	\$0.00	\$0.00
4. Induced Utilization Adjustment	0.000	0.000

VII. Development of Supplemental Premium:					
	At 0.000				
1. Part D Covered Drugs	\$0.00				
2. Non Part D Covered Drugs	\$0.00				
3. Less Basic Covered	\$0.00				
4. Supplemental Coverage	\$0.00				
5. Reduction in Reinsurance	\$0.00				
6. Additional Non-Benefit Expenses	\$0.00				
7. Additional Gain/(Loss)	\$0.00				
8. Supplemental Premium	\$0.00				

Contract Number:	4. Contract Yr:	2020	7. Plan Name:		10. VBID:	N	13. PD Region:
2. Plan ID:	5. Org. Name:		8. Plan Type:		11. MTM:	N	14. PD Benefit Type:
3. Segment ID:	6. SNP:		9. Enrollee Type:		12. ESRD-SNP:	N	15. SNP Type:
II. Projections for Equivalenc	a Tasts	(f)	(g)	(h)	(i)	(i)	(k)
ii. I Tojections for Equivalent	C ICSIS	(1)	(9)	(11)	(1)	U/	(1/)
Population Not Exceeding \$3		(1) De	fined Standard Cove	(* - /	Actua	arially Equivalent or A	· · · · · · · · · · · · · · · · · · ·
•		Number of Scripts	(5)	(* - /	Actua Number of Scrip	<u> </u>	Iternative Benefits
Population Not Exceeding \$3			fined Standard Cove	rage	_	<u> </u>	Iternative Benefits

II. Projections for Equivalence Tests	(f)	(g)	(h)	(i)	(j)	(k)	
Population Not Exceeding \$3,820 with Std Coverage		fined Standard Covera	<u> </u>	Actuarially Equivalent or Alternative Benefits			
All Spending	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$	
1. Retail Generic							
2. Retail Preferred Brand							
3. Retail Non-Preferred Brand							
4. Retail Specialty							
5. Mail Order Generic							
6. Mail Order Preferred Brand							
7. Mail Order Non-Preferred Brand							
8. Mail Order Specialty							
09. Total	0	\$0.00	\$0.00	0	\$0.00	\$0.00	
Population Exceeding \$3,820 with Std Coverage							
	Noveles and Contrate	Allanna d 🕏	Ctal Coot Charina	Normalis and A Cambridge	Allance of C	On at Objective of	
All Spending	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$	
10. Retail Generic							
11. Retail Preferred Brand							
12. Retail Non-Preferred Brand							
13. Retail Specialty							
14. Mail Order Generic							
15. Mail Order Preferred Brand							
16. Mail Order Non-Preferred Brand							
17. Mail Order Specialty							
18. Total	0	\$0.00		0	\$0.00		
Amounts Allocated Up to ICL	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$ (1)	
19. Retail Generic		1 m 2 m 2 m 2	, , , , , , , , , , , , , , , , , , ,		1	σ σ σ σ σ σ σ σ σ σ σ σ σ σ σ σ σ σ σ	
20. Retail Preferred Brand							
21. Retail Non-Preferred Brand							
22. Retail Specialty 23. Mail Order Generic							
23. Mail Order Generic 24. Mail Order Preferred Brand							
25. Mail Order Non-Preferred Brand							
26. Mail Order Specialty							
27. Total	0	\$0.00	\$0.00	0	\$0.00	\$0.00	
Amounts Allocated over Catastrophic Coverage	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$	
28. Retail Generic							
29. Retail Preferred Brand							
30. Retail Non-Preferred Brand							
31. Retail Specialty							
32. Mail Order Generic							
33. Mail Order Preferred Brand							
34. Mail Order Non-Preferred Brand							
35. Mail Order Specialty							
36. Total	0	\$0.00	\$0.00	0	\$0.00	\$0.00	
	Number of Scripts	Allowed \$	Std Cost Sharing \$	Number of Scripts	Allowed \$	Cost Sharing \$	
37. Non-Part D Covered Drugs - All Spending	rtumber er eeripte	/ III o II o II o	ota oot onamg v	realiser or compto	/ mowod \$	oost onaring ¢	
NETWORK PRICING	GEN	ERIC	BRA	ND	SPECIA	ALTY	
	% discount off AWP	Dispensing Fee	% discount off AWP	Dispensing Fee	% discount off AWP	Dispensing Fee	
RETAIL							
MAIL							

WORKSHEET 6A - COVERAGE IN THE GAP
Page 7 of 8

I. General Information

1. Contract Number:	Contract Yr:	2020	7. Plan Name:	10. VBID:	N	13. PD Region:
2. Plan ID:	5. Org. Name:		8. Plan Type:	11. MTM:	N	14. PD Benefit Type:
3. Segment ID:	6. SNP:		9. Enrollee Type:	12. ESRD-SNP:	N	15. SNP Type: N/A

II. Spending in the Coverage Gap (f) (j) (k) (g) (h) Population Exceeding \$3,820 with Std Coverage **Defined Standard Coverage Actuarially Equivalent or Alternative Benefits** Amounts Allocated between \$3,820 and Catastrophic **Number of Scripts** Allowed \$ Std Cost Sharing \$ Number of Scripts Allowed \$ Cost Sharing \$ 1. Retail Generic \$0.00 \$0.00 \$0.00 \$0.00 2. Retail Preferred Brand \$0.00 \$0.00 \$0.00 \$0.00 3. Retail Non-Preferred Brand 0 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00 1. Retail Specialty Generic 0 \$0.00 \$0.00 5. Retail Specialty Brand 0 \$0.00 \$0.00 \$0.00 \$0.00 6. Mail Order Generic \$0.00 \$0.00 \$0.00 \$0.00 0 7. Mail Order Preferred Brand 0 \$0.00 \$0.00 \$0.00 \$0.00 8. Mail Order Non-Preferred Brand 0 \$0.00 \$0.00 \$0.00 \$0.00 9. Mail Order Specialty Generic 0 \$0.00 \$0.00 \$0.00 \$0.00 10. Mail Order Specialty Brand 0 \$0.00 \$0.00 \$0.00 \$0.00 11. Total 0 \$0.00 \$0.00 0 \$0.00 \$0.00 Low Income Population Amounts Allocated between \$3,820 and Catastrophic **Number of Scripts** Allowed \$ Std Cost Sharing \$ **Number of Scripts** Allowed \$ Cost Sharing \$ 12. Retail Generic 13. Retail Preferred Brand 14. Retail Non-Preferred Brand 15. Retail Specialty Generic 16. Retail Specialty Brand 17. Mail Order Generic 18. Mail Order Preferred Brand 19. Mail Order Non-Preferred Brand 20. Mail Order Specialty Generic 21. Mail Order Specialty Brand 0 0 22. Total \$0.00 \$0.00 \$0.00 \$0.00 Non-Low Income Population Amounts Allocated between \$3,820 and Catastrophic **Number of Scripts** Allowed \$ **Std Cost Sharing \$ Number of Scripts** Allowed \$ Cost Sharing \$ 23. Retail Generic 24. Retail Preferred Brand 25. Retail Non-Preferred Brand 26. Retail Specialty Generic 27. Retail Specialty Brand 28. Mail Order Generic 29. Mail Order Preferred Brand 30. Mail Order Non-Preferred Brand 31. Mail Order Specialty Generic 32. Mail Order Specialty Brand 0 \$0.00 \$0.00 0 \$0.00 33. Total \$0.00

Non-LI Generics in Gap PMPM
Non-LI Brand Discount Amt PMPM

\$0.00 \$0.00

Contract Number:	4. Contract Yr: 2020	7. Plan Name:	10. VBID:	N	13. PD Region:
2. Plan ID:	5. Org. Name:	8. Plan Type:	11. MTM:	N	14. PD Benefit Type:
3. Segment ID:	6. SNP:	9. Enrollee Type:	12. ESRD-SNP:	N	15. SNP Type: N/A

II. 2020 Defined Standard Benefit Parameters

1. Deductible	\$415
2. Initial Coverage Limit	\$3,820
3. Out-of-pocket Limit	\$5,100

III. Summary of Key Bid Elements

in Cummary of its j = ia = iomorits	
1. Standardized Part D Bid	\$0.00
2. National Average Monthly Bid Amount	
3. Base Beneficiary Premium	
4. MTM Performance Payment	
Basic Part D Premium (prior to A/B rebate allocation)	
5. Unrounded	\$0.00
6. Rounded	\$0.00
Supplemental Part D Premium (prior to A/B rebate allocation)	
7. Unrounded	\$0.00
8. Rounded	\$0.00
Prospective federal reinsurance (non-standardized)	\$0.00
10. Prospective low-income cost sharing subsidy (non-standardized)	\$0.00
11. Target amount adjustment (allowed costs as a ratio of bid)	1.0000
12. Prospective brand discount amount	\$0.00
Rounding Rule	
13. Round Part D premiums to nearest	\$0.10

IV. Part D Bid Pricing Tool Contacts

Plan Bid Contact		
Name		
Phone		
Email		
Part D Certifying Actuary		
Name and Credentials		
Phone		
Email		
Part D Additional BPT Actuarial Contact		
Name		
Phone		
Email		
Date Prepared		

V. Working Model Text Box